Login to Your Account



Financings Roundup

Pluristem Raising $32M Publicly as PLX Pipeline Gains Attention

By Jennifer Boggs
Managing Editor

Monday, September 17, 2012

Taking advantage of a summer stock climb on the back of its allogeneic cell therapy pipeline, Pluristem Therapeutics Inc. is nearly doubling its cash position with a $32 million public offering.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription